

Supplemental Table 2. Pairwise analysis of the clinico-pathological and treatment characteristics according to the presence metastatic peritoneal involvement with or without ascites in the developing set of patients with MSI-high/dMMR mCRC (Cohort 1).

Characteristics	A - No peritoneal metastases (N=305) N (%)	B - Peritoneal metastases without ascites (N=172) N (%)	C - Peritoneal metastases with ascites (N=25) N (%)	B vs A <i>p</i> *	C vs A <i>p</i> *	C vs B <i>p</i> *
Sex				0.567	0.532	0.674
Female	135 (44.3)	81 (47.1)	13 (52.0)			
Male	170 (55.7)	91 (52.9)	12 (48.0)			
Age (years)				0.323	0.468	0.236
<70	233 (76.4)	124 (72.1)	21 (84.0)			
≥70	72 (23.6)	48 (27.9)	4 (16.0)			
ECOG PS				0.924	0.006	0.009
0	149 (48.9)	83 (48.3)	5 (20.0)			
≥1	156 (51.1)	89 (51.7)	20 (80.0)			
Primary tumor resection				0.084	0.796	0.762
No	62 (20.3)	24 (14.0)	4 (16.0)			
Yes	243 (79.7)	148 (86.0)	21 (84.0)			
Primary tumor sidedness				0.021	0.197	0.813
Left	118 (38.7)	48 (27.9)	6 (24.0)			
Right	187 (61.3)	124 (72.1)	19 (76.0)			
NA						
RAS mutational status				0.414	0.048	0.107
Wild-type	186 (61.0)	110 (64.0)	21 (84.0)			
RAS mutated	108 (35.4)	53 (30.8)	4 (16.0)			
NA	11 (3.6)	9 (5.2)	0 (0.0)			
BRAF mutational status				0.321	0.056	0.166
Wild-type	221 (72.5)	116 (67.4)	14 (56.0)			
BRAF mutated	73 (23.9)	48 (27.9)	11 (44.0)			
NA	11 (3.6)	8 (4.67)	0 (0.0)			
Synchronous metastases				0.390	0.302	0.198
No	145 (47.5)	88 (51.2)	9 (36.0)			
Yes	160 (52.5)	82 (47.6)	16 (64.0)			
NA	0 (0.0)	2 (1.2)	0 (0.0)			
Liver metastases				<0.001	0.060	0.625
No	157 (51.5)	131 (76.2)	18 (72.0)			
Yes	148 (48.5)	41 (23.8)	7 (28.0)			
Lung metastases				0.048	0.437	>0.999
No	241 (79.0)	149 (86.6)	22 (88.0)			
Yes	64 (21.0)	23 (13.3)	3 (12.0)			
Lymph nodal metastases				<0.001	0.187	0.520
No	101 (33.1)	97 (56.4)	12 (48.0)			
Yes	204 (66.9)	75 (43.6)	13 (52.0)			
Bone metastases				0.352	0.636	0.218
No	289 (94.8)	167 (97.1)	23 (92.0)			
Yes	16 (5.2)	5 (2.9)	2 (8.0)			

Number of metastatic sites				<0.001	0.021	0.654
1	162 (53.1)	58 (33.7)	7 (28.0)			
≥2	143 (46.9)	114 (66.3)	18 (72.0)			
Prior systemic treatment for metastatic disease				0.281	0.128	0.380
No	65 (21.3)	29 (16.9)	2 (8.0)			
Yes	240 (78.7)	143 (83.1)	23 (92.0)			
ICI regimen				0.045	>0.999	0.279
a-PD(L)-1	211 (69.2)	103 (59.9)	18 (72.0)			
a-PD-1 + a-CTLA-4	94 (30.8)	69 (40.1)	7 (28.0)			
*Pairwise Fisher's exact test						